(Q36268315)

13 August 2017

Second-generation kinase inhibitors (English)

1 reference

13 August 2017

Bert M Klebl

1

1 reference

PubMed ID

16185153

13 August 2017

Gerhard Müller

series ordinal

2

1 reference

PubMed ID

16185153

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

Expert Opinion on Therapeutic Targets

13 August 2017

1 reference

13 August 2017

9

1 reference

13 August 2017

5

1 reference

13 August 2017

975-993

1 reference

The protein kinase complement of the human genome

13 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

The regulation of protein function by multisite phosphorylation--a 25 year update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Tyrosine kinase inhibitors: from rational design to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Leptinomimetic effects of the AMP kinase activator AICAR in leptin-resistant rats: prevention of diabetes and ectopic lipid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

The development and therapeutic potential of protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

21 January 2018

Erlotinib hydrochloride

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Specificity and mechanism of action of some commonly used protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Rho kinase, a promising drug target for neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

The specificities of protein kinase inhibitors: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Evaluation of kinase inhibitor selectivity by chemical proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Rho/Rho-kinase mediated signaling in physiology and pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Design and synthesis of Rho kinase inhibitors (I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

The ups and downs of Rho-kinase and penile erection: upstream regulators and downstream substrates of rho-kinase and their potential role in the erectile response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

An essential part for Rho-associated kinase in the transcellular invasion of tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Medicinal chemistry of target family-directed masterkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Strategies to overcome resistance to targeted protein kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Src inhibitors: genomics to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

ErbB-targeted therapeutic approaches in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Epidermal growth factor receptor: mechanisms of activation and signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

21 January 2018

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Gefitinib does not increase survival in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

1001 protein kinases redux--towards 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Protein kinase activity associated with the avian sarcoma virus src gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Transforming gene product of Rous sarcoma virus phosphorylates tyrosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Aurora-kinase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Novel chemical genetic approaches to the discovery of signal transduction inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Use of a drug-resistant mutant of stress-activated protein kinase 2a/p38 to validate the in vivo specificity of SB 203580.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Strategies toward the design of novel and selective protein tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Kinomics-structural biology and chemogenomics of kinase inhibitors and targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

An efficient proteomics method to identify the cellular targets of protein kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Intracellular Targets of Paullones. Identification following affinity purification on immobilized inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Synthesis and target identification of hymenialdisine analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

The IKK NF-kappa B system: a treasure trove for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Tyrosine kinase inhibitors: a new approach for asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Glycogen synthase kinase 3: a drug target for CNS therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Specific Inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

A new modality for immunosuppression: targeting the JAK/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Kinases as therapeutic targets for heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Activation and function of cyclin T-Cdk9 (positive transcription elongation factor-b) in cardiac muscle-cell hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.975

21 January 2018

Identifiers

DOI

10.1517/14728222.9.5.975

1 reference

13 August 2017

1 reference

PubMed ID

16185153